EP3091030A4 - Anti-human-rankl-antikörper, humanisierter antikörper, pharmazeutische zusammensetzungen und verwendungen davon - Google Patents

Anti-human-rankl-antikörper, humanisierter antikörper, pharmazeutische zusammensetzungen und verwendungen davon Download PDF

Info

Publication number
EP3091030A4
EP3091030A4 EP14876325.3A EP14876325A EP3091030A4 EP 3091030 A4 EP3091030 A4 EP 3091030A4 EP 14876325 A EP14876325 A EP 14876325A EP 3091030 A4 EP3091030 A4 EP 3091030A4
Authority
EP
European Patent Office
Prior art keywords
antibody
pharmaceutical compositions
human rankl
humanized antibody
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14876325.3A
Other languages
English (en)
French (fr)
Other versions
EP3091030B1 (de
EP3091030A1 (de
Inventor
Qing Zhou
Xiao Feng
Weihong NIAN
Lingyun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genor Biopharma Co Ltd
Original Assignee
Genor Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genor Biopharma Co Ltd filed Critical Genor Biopharma Co Ltd
Publication of EP3091030A1 publication Critical patent/EP3091030A1/de
Publication of EP3091030A4 publication Critical patent/EP3091030A4/de
Application granted granted Critical
Publication of EP3091030B1 publication Critical patent/EP3091030B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14876325.3A 2013-12-31 2014-12-28 Anti-human-rankl-antikörper, humanisierter antikörper, pharmazeutische zusammensetzungen und verwendungen davon Active EP3091030B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310753972.3A CN103965357B (zh) 2013-12-31 2013-12-31 一种抗人rankl抗体
PCT/CN2014/095236 WO2015101241A1 (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途

Publications (3)

Publication Number Publication Date
EP3091030A1 EP3091030A1 (de) 2016-11-09
EP3091030A4 true EP3091030A4 (de) 2017-11-29
EP3091030B1 EP3091030B1 (de) 2020-07-15

Family

ID=51235400

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14876325.3A Active EP3091030B1 (de) 2013-12-31 2014-12-28 Anti-human-rankl-antikörper, humanisierter antikörper, pharmazeutische zusammensetzungen und verwendungen davon

Country Status (5)

Country Link
US (1) US9896510B2 (de)
EP (1) EP3091030B1 (de)
CN (4) CN103965357B (de)
ES (1) ES2824101T3 (de)
WO (1) WO2015101241A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
KR102516712B1 (ko) * 2014-11-14 2023-03-31 프로바이오콘 게엠베하 전이성 질환을 치료하기 위한 rankl-특이적 제제
EP3085709B1 (de) * 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanisierte antikörper gegen menschliches rankl, pharmazeutische zusammensetzung und verwendung davon
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
US10913799B2 (en) * 2016-10-28 2021-02-09 Eli Lilly And Company Anti-RANKL antibodies and uses thereof
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
PL3615066T3 (pl) 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
CN116375866B (zh) * 2017-10-27 2026-02-17 河北药明生物技术有限公司 靶向rankl的治疗性抗体
EP3773629A4 (de) * 2018-03-27 2022-01-19 AZTherapies, Inc. Car-treg-basierte therapien zur behandlung von neurodegenerativen erkrankungen
CN108753920A (zh) * 2018-06-21 2018-11-06 佛山安普泽生物医药股份有限公司 一种检测rankl靶向治疗药物生物学活性的方法
CN110878319A (zh) * 2018-09-06 2020-03-13 上海张江生物技术有限公司 一种tnf相关激活诱导细胞因子的制备方法
CN109504682A (zh) * 2018-11-09 2019-03-22 佛山安普泽生物医药股份有限公司 一种dna分子、慢病毒载体、细胞株及其应用
JP7671275B2 (ja) * 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
US12679900B2 (en) * 2019-12-13 2026-07-14 Biosion Inc. Antibodies binding RANKL and uses thereof
CN118440203A (zh) * 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
CN111808198B (zh) * 2020-07-27 2022-06-03 广东安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
CN114099672B (zh) * 2022-01-28 2022-05-06 嘉和生物药业有限公司 具有增强稳定性的抗rankl人源化单克隆抗体的药物组合物
CN117285637B (zh) * 2023-11-22 2024-03-22 江苏迈威康新药研发有限公司 一种抗独特型抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002713A2 (en) * 2001-06-26 2003-01-09 Abgenix, Inc. Antibodies to opgl
WO2010022120A1 (en) * 2008-08-19 2010-02-25 Regeneron Pharmaceuticals, Inc. Human antibodies to human rankl
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2012163887A1 (en) * 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1278778A2 (de) 2000-05-03 2003-01-29 Amgen Inc., Modifizierte peptide, die eine fc-domäne behalten, als therapeutische agenzien
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
MX2009012650A (es) * 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
CN101845098B (zh) * 2009-03-26 2015-07-01 中国人民解放军总医院 鼠rank/rankl胞外复合体的晶体,制备其的方法及其应用
CN102741286B (zh) * 2010-03-26 2013-12-25 刘庆法 以pae技术开发的抗人rankl单抗及其应用
CN102241776B (zh) * 2010-05-25 2013-05-08 首都医科大学 Rankl-tnf样区融合蛋白及其制备方法和应用
WO2012133914A1 (ja) * 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
CN103060274B (zh) * 2012-12-28 2013-12-11 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002713A2 (en) * 2001-06-26 2003-01-09 Abgenix, Inc. Antibodies to opgl
WO2010022120A1 (en) * 2008-08-19 2010-02-25 Regeneron Pharmaceuticals, Inc. Human antibodies to human rankl
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2012163887A1 (en) * 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Alignment heavy chains EP14876325.3", 14 July 2017 (2017-07-14), XP055391054, Retrieved from the Internet <URL:q/ibis> [retrieved on 20170714] *
EDWARD M SCHWARZ ET AL: "Clinical development of anti-RANKL therapy", ARTHRITIS RESEARCH & THERAPY, 1 January 2007 (2007-01-01), England, pages S7 - S7, XP055284385, Retrieved from the Internet <URL:http://download.springer.com/static/pdf/345/art%3A10.1186%2Far2171.pdf?originUrl=http://arthritis-research.biomedcentral.com/article/10.1186/ar2171&token2=exp=1467187444~acl=/static/pdf/345/art%253A10.1186%252Far2171.pdf*~hmac=dcc1b63c7bab125a450b9d03f4a86c100fe6ab415900246a54d123139da980a2> [retrieved on 20170714], DOI: 10.1186/ar2171 *
See also references of WO2015101241A1 *

Also Published As

Publication number Publication date
CN109517067A (zh) 2019-03-26
CN105732812A (zh) 2016-07-06
EP3091030B1 (de) 2020-07-15
CN103965357A (zh) 2014-08-06
CN105732812B (zh) 2019-03-08
WO2015101241A1 (zh) 2015-07-09
CN105102482B (zh) 2019-02-01
US9896510B2 (en) 2018-02-20
US20160333101A1 (en) 2016-11-17
CN103965357B (zh) 2016-08-17
EP3091030A1 (de) 2016-11-09
ES2824101T3 (es) 2021-05-11
CN105102482A (zh) 2015-11-25
CN109517067B (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
IL281731A (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
IL272615B (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
AU2014347565A1 (en) Antigen-binding molecule containing modified antibody variable region
EP3070168A4 (de) Antigenbindendes molekül mit modifizierter variabler antikörperregion
EP3480215B8 (de) Antikörper gegen her2 und konjugat daraus
EP3003390A4 (de) Anti-c10orf54-antikörper und verwendungen davon
EP3083698A4 (de) Monoklonale anti-tk1-antikörper
EP3066470A4 (de) Humanisierter anti-ceacam5-antikörper und verwendungen davon
EP3026062A4 (de) Anti-pd1-antikörper und verwendung davon
ZA201507021B (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
IL261547B (en) Antibodies against pesidine and their uses
EP3081576A4 (de) Pd-1-antikörper, antigenbindendes fragment davon und medizinische anwendung davon
IL240443A0 (en) Antibodies against tnf-a with a high level of galactosylation and their uses
EP3089994A4 (de) Fabs-in-tandem-immunglobulin und verwendungen davon
EP3024850A4 (de) Monoklonale anti-galectin-1-antikörper und fragmente davon
EP3088519A4 (de) Neuartige antikörper gegen menschliches bdca-2
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
EP2970445A4 (de) Humanisierte anti-n2-antikörper
EP3042956A4 (de) Spezifisch mit menschlichem integrin a6b4 reagierender antikörper
ZA201504748B (en) New antibody fragments, compositions and uses thereof
EP3065774A4 (de) Anti-ccl17-antikörper
EP3481863A4 (de) Humanisierter anti-s100a9-antikörper und verwendungen davon
EP3109320A4 (de) Neuer anti-human-pai-1-antikörper
EP3239177A4 (de) Neuartiger egfrviii-antikörper und zusammensetzung damit
EP3066122A4 (de) Monoklonaler prä-haptoglobin-2-antikörper und verwendungen davon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20170720BHEP

Ipc: A61P 19/08 20060101ALI20170720BHEP

Ipc: A61P 19/10 20060101ALI20170720BHEP

Ipc: A61P 19/02 20060101ALI20170720BHEP

Ipc: A61K 39/395 20060101ALI20170720BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20171103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20171026BHEP

Ipc: A61P 19/08 20060101ALI20171026BHEP

Ipc: A61K 39/395 20060101ALI20171026BHEP

Ipc: C07K 16/28 20060101AFI20171026BHEP

Ipc: A61P 19/10 20060101ALI20171026BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181030

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200127

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014067878

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1290930

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200815

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DENNEMEYER AG, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1290930

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201016

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201015

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201116

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201015

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201115

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014067878

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2824101

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210511

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

26N No opposition filed

Effective date: 20210416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251117

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251117

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251117

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260119

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251222

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251231

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260101

Year of fee payment: 12